SEC Form 4 · accession 0001209191-15-016079

Mirati Therapeutics, Inc. · MRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP & Chief Scientific Officer

Period of report

Feb 17, 2015

Accepted (ET)

Feb 19, 2015 · 4:42 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001576263

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Feb 17, 2015	S	1,250	$22.29	D	1,250	D
Common Stock	Feb 17, 2015	M	400	$8.50	A	1,650	D
Common Stock	Feb 17, 2015	S	400	$23.10	D	1,250	D
Common Stock	Feb 19, 2015	M	3,100	$8.50	A	4,350	D
Common Stock^F2	Feb 19, 2015	S	3,100	$23.0245	D	1,250	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F3	$8.50	Feb 17, 2015	M	400	D	—	Jul 16, 2020	Common Stock	400	27,100	D
Employee Stock Option (Right to Buy)^F3	$8.50	Feb 19, 2015	M	3,100	D	—	Jul 16, 2020	Common Stock	3,100	24,000	D

F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.0756, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3Twenty percent (20%) of the shares subject to the stock option vested and became exercisable on the grant date of the option (July 17, 2013), and an additional 20% shall vest and become exercisable each year on the anniversary of the grant date.